Sector News

Celgene Corporation Announces the Appointment of Gerald F. Masoudi as Executive Vice President, General Counsel and Corporate Secretary

April 2, 2015
Life sciences
Celgene Corporation (CELG) today announced the appointment of Gerald F. Masoudi as Executive Vice President, General Counsel and Corporate Secretary, effective June 1, 2015. Mr. Masoudi will be responsible for global legal strategy and will serve on the company’s Executive Committee.
 
Mr. Masoudi will succeed Lawrence V. Stein, Celgene’s Executive Vice President, General Counsel and Corporate Secretary since 2012, who is retiring from Celgene following a distinguished business and legal career that also included serving as General Counsel for Wyeth and Genetics Institute and as a partner at the law firm Arnold & Porter.
 
“Larry Stein has served as a valued member of Celgene’s senior leadership team and provided the company important strategic legal counsel,” said Robert J. Hugin, Chairman and CEO of Celgene Corporation. “Celgene is deeply grateful for Larry’s significant contributions during his tenure as General Counsel.”
 
“Jerry brings a wealth of experience to Celgene” said Mr. Hugin. “His deep understanding of regulatory policy and his significant healthcare-related legal expertise will add valuable perspective to our leadership team.”
 
Mr. Masoudi joins Celgene from Covington & Burling LLP, a leading international law firm, where he is a partner and serves as co-chair of the Food and Drug practice group. At Covington, he has advised multinational companies and trade associations on significant litigation, enforcement, regulatory and public policy matters. Before joining Covington, Mr. Masoudi served as Chief Counsel of the U.S. Food and Drug Administration. Before joining FDA, Mr. Masoudi served as Deputy Assistant Attorney General for international, policy and appellate matters in the Antitrust Division of the U.S. Department of Justice. Before his government service, Mr. Masoudi was a trial and litigation partner with the law firm Kirkland & Ellis. Immediately following his graduation from law school, he clerked for Judge Frank H. Easterbrook of the U.S. Court of Appeals for the Seventh Circuit.
 
Mr. Masoudi received his J.D. from The University of Chicago Law School, graduating with high honors and serving on the editorial board of the Law Review. He received his B.A. in economics from Amherst College, Phi Beta Kappa.
 
Source: Celgene

comments closed

Related News

May 4, 2024

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio

Life sciences

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.

May 4, 2024

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Life sciences

The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.

May 4, 2024

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Life sciences

Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.

How can we help you?

We're easy to reach